

Response to Reviewers

Thank you to the reviewer for providing us with such thorough feedback and comments on our manuscript. Here, we have addressed each of the comments.

1. The hypothesis and novelty of this work should be added at the end of the "Introduction section".

We hypothesize that development of irAEs, specifically endocrine adverse events, will have a positive correlation with PFS and OS in patients treatment with ICPI. We also anticipate that there will be differences in outcomes among various racial groups. There is very limited data on efficacy outcomes in racially diverse patients who receive immunotherapy and develop irAEs making our study unique and clinically relevant.

2. Ethical code No. must be mentioned.

STUDY00001266.

3. The discussion section must be improved and expanded.

Additional information in the discussion and conclusion section was added.

4. The significance level between groups must be mentioned in "Results section"

Statistical significance between groups was defined as $p < 0.05$.